Brief: Richard Kayne- After Decision To Discontinue Interferon Lambda, Have Further Considered Eiger Biopharmaceuticals' Stated Strategic Objectives
20/10/2023 21:57
Oct 20 (Reuters) - Eiger BioPharmaceuticals Inc
EIGR.O :
* RICHARD KAYNE- AFTER DECISION TO DISCONTINUE INTERFERON
LAMBDA,
HAVE FURTHER CONSIDERED EIGER BIOPHARMACEUTICALS' STATED
STRATEGIC OBJECTIVES
* RICHARD KAYNE- MAY SEEK TO PARTICIPATE, POTENTIALLY ENGAGE
IN OR
MAKE PROPOSALS WITH EIGER, OR MAY CHANGE INTENTION WITH RESPECT
TO INTERFERON LAMBDA
Source text for Eikon: ID:
Further company coverage: EIGR.O
Recent news on Eiger Biopharmaceuticals
See all newsBrief: Eiger Biopharmaceuticals On Sept 5, Bankruptcy Court Entered Order Confirming Fifth Amended Joint Plan Of Liquidation Of Co & Its Debtor Affiliates
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
Brief: Eiger Biopharmaceuticals And Amylyx Entered Into An Asset Purchase Agreement
Eiger BioPharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Eiger BioPharmaceuticals Inc expected to post a loss of $7.50 a share - Earnings Preview